文献速递血栓与止血

针对人类血小板同种抗原HPA-1a(PlA1)的多克隆免疫反应的高分辨率图谱绘制

High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1).
PubMed 文献 · Blood Adv · 2018-01-01

研究用表达人源化鼠GPIIIa亚型的转基因小鼠,分析单克隆和多克隆HPA-1a特异性抗体结合所需分子条件。结果显示,人源化PSI结构域足以重建部分抗体识别的HPA-1a表位,而另一些抗体还需人源化EGF1结构域中的特定氨基酸。该发现揭示针对HPA-1a的多克隆同种免疫反应存在复杂的异质性。

要点

  • 人源化鼠GPIIIa的PSI结构域足以重建部分HPA-1a特异性抗体识别的表位。
  • 另一些HPA-1a特异性抗体的结合还需人源化EGF1结构域中的特定氨基酸。
  • 针对HPA-1a的多克隆同种免疫反应存在既往未料到的复杂异质性。

核心结论

  • 针对HPA-1a的多克隆同种免疫反应存在复杂的异质性,不同HPA-1a特异性抗体对PSI和EGF1结构域人源化残基的要求不同。

研究设计与样本

  • 研究生成表达鼠GPIIIa(muGPIIIa)亚型的转基因小鼠,这些亚型在PSI和EGF1结构域内携带选定的人源化残基,并检测其支持一系列单克隆和多克隆HPA-1a特异性抗体结合的能力。

主要发现

  • 人源化muGPIIIa的PSI结构域足以重建部分HPA-1a特异性抗体所识别的HPA-1a表位。
  • 人源化线性距离远但构象靠近的EGF1结构域内的不同氨基酸是另一些HPA-1a特异性抗体结合所必需的。

关键数值与推荐

  • HPA-1a/1b(PlA1/A2)同种抗原系统由人血小板膜糖蛋白(GP)IIIa的Leu33Pro多态性控制,约占胎儿/新生儿同种免疫性血小板减少症(FNAIT)病例的80%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibodies to platelet-specific antigens are responsible for 2 clinically important bleeding disorders: posttransfusion purpura and fetal/neonatal alloimmune thrombocytopenia (FNAIT). The human platelet-specific alloantigen 1a/1b (HPA-1a/1b; also known as PlA1/A2) alloantigen system of human platelet membrane glycoprotein (GP) IIIa is controlled by a Leu33Pro polymorphism and is responsible for ∼80% of the cases of FNAIT. Local residues surrounding polymorphic residue 33 are suspected to have a profound effect on alloantibody binding and subsequent downstream effector events. To define the molecular requirements for HPA-1a alloantibody binding, we generated transgenic mice that expressed murine GPIIIa (muGPIIIa) isoforms harboring select humanized residues within the plexin-semaphorin-integrin (PSI) and epidermal growth factor 1 (EGF1) domains and examined their ability to support the binding of a series of monoclonal and polyclonal HPA-1a-specific antibodies. Humanizing the PSI domain of muGPIIIa was sufficient to recreate the HPA-1a epitope recognized by some HPA-1a-specific antibodies; however, humanizing distinct amino acids within the linearly distant but conformationally close EGF1 domain was required to enable binding of others. These results reveal the previously unsuspected complex heterogeneity of the polyclonal alloimmune response to this clinically important human platelet alloantigen system. High-resolution mapping of this alloimmune response may improve diagnosis of FNAIT and should facilitate the rational design and selection of contemplated prophylactic and therapeutic anti-HPA-1a reagents.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zhi H, Ahlen MT, Thinn AMM, et al. High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1). Blood Adv. 2018. PMID: 30413435. doi:10.1182/bloodadvances.2018023341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。